Regulation
Galaxy Therapeutics secures CE mark for embolisation system
Galaxy Therapeutics obtained CE mark approval for its saccular endovascular aneurysm lattice (SEAL) embolisation system. The company plans a phased commercial rollout across select European markets following the regulatory clearance.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network